News | December 10, 2010

Transcatheter Aortic Valve Gains CE Mark for Subclavian Access


December 10, 2010 – European CE mark approval has been granted so the Medtronic CoreValve transcatheter aortic valve replacement system can be delivered through the subclavian artery, located beneath the collar bone.

As a result of this new vascular access point, thousands more patients in Europe with severe aortic stenosis may be eligible to receive transcatheter aortic valve implantation (TAVI). Since 2007, the CoreValve system has been implanted in more than 12,000 people in 34 countries. It was previously only available through femoral access delivery.

The CoreValve System is designed to provide a nonsurgical aortic valve replacement option for patients with severe aortic stenosis who are at high or prohibitive risk for open?heart surgery. Transcatheter valves are typically implanted through the femoral artery in the leg. However, there are thousands of people whose femoral arteries are too narrow or are compromised due to disease.

“The subclavian approach will give physicians expanded access to care for a significant underserved subset of patients for whom femoral delivery is not possible or desirable. Given the sheer number of patients with severe aortic stenosis along with the aging population, the need for new approaches to valve replacement continues to increase,” said Neil Moat, MBBS, MS, FRCS and consultant cardiac surgeon at The Royal Brompton Hospital in London.

Medtronic will begin training physicians on the subclavian technique in the coming weeks.

The valve is currently limited to investigational use in the United States.

For more information: www.medtronic.com


Related Content

News | Heart Valve Technology

Aug. 4, 2025 — Corcym announced that its Perceval Plus sutureless aortic heart valve was used in a first-ever robotic ...

Home August 05, 2025
Home
News | Heart Valve Technology

July 10, 2025 — On July 2, 2025, Centers for Medicare & Medicaid Services (CMS) issued a National Coverage Determination ...

Home July 11, 2025
Home
News | Heart Valve Technology

June 27, 2025 – Foldax Inc., a leader in the development of innovative polymer heart valves, has announced compelling ...

Home June 27, 2025
Home
News | Heart Valve Technology

June 04, 2025 — HeartSciences Inc. has announced that the U.S. Food and Drug Administration has granted Breakthrough ...

Home June 12, 2025
Home
News | Heart Valve Technology

May 27, 2025 — Abbott has announced the U.S. Food and Drug Administration (FDA) has approved the company's Tendyne ...

Home May 28, 2025
Home
News | Heart Valve Technology

May 2, 2025 – New analysis from the EARLY TAVR trial showed patients between the age of 65 and 70 years old derived the ...

Home May 02, 2025
Home
News | Heart Valve Technology

April 28, 2025 — The Society of Thoracic Surgeons (STS) has launched its latest surgical risk calculator designed for ...

Home April 29, 2025
Home
News | Heart Valve Technology

March 30, 2025 — Medtronic has announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Data ...

Home March 31, 2025
Home
News | Heart Valve Technology

Feb. 22, 2025 — More than 60,000 people die from heart valve disease (HVD) in the U.S. each year, according to the ...

Home March 04, 2025
Home
News | Heart Valve Technology

Feb. 17, 2025 — The International Consortium for Health Outcomes Measurement (ICHOM) has developed a globally inclusive ...

Home February 18, 2025
Home
Subscribe Now